Spherix generates revenue through acquiring and licensing patent portfolios. It has over 200 patents of its own covering various industries and is engaged in ongoing licensing campaigns. It has a relationship with Rockstar Consortium, which gives it access to over 4000 additional patents. Spherix recently acquired a portfolio of 222 patents from Harris Corporation covering 15 years of research across many technologies.
Spherix generates licensing revenues by investing in and acquiring patent assets, then monetizing those patents. In December 2013, Spherix acquired patents from Rockstar Consortium for $60 million in stock. Rockstar was formed by Apple, Microsoft, Sony, Blackberry and Ericsson to acquire the valuable Nortel patent portfolio. Spherix is asserting some of these patents against Cisco Systems and others and seeking licenses from data, voice, optical and access equipment companies. Management seeks to maximize patent value through litigation, licensing campaigns and new partnerships.
Angel investors provide seed funding and support for early stage ventures in exchange for equity, targeting higher returns than public markets; they are typically wealthy individuals who contribute time, experience and contacts in addition to money. Regulations require that angel investments follow securities laws to protect both entrepreneurs and investors, with legal oversight of offering documents and investor awareness of risks. As a wealth manager, one could suggest clients consider angel investing if they meet criteria like high income and net worth, entrepreneurial experience, and willingness to hold investments long-term in high-risk sectors like healthcare, software or biotech.
Building a High Value Patent Portfolio: Where Strength Meets QualityErik Oliver
Join Gene Quinn, patent attorney and founder of IPWatchdog.com and Erik Reeves, Founder of AcclaimIP and CTO of Anaqua, and Kent Richardson for a free webinar discussion on building a portfolio versus buying patents, identifying gaps in your patent coverage, and unlocking the secrets of your own patent portfolio to identify needs.
This document summarizes key findings from the 2019 Global Family Office Report. It was prepared by Campden Wealth Limited using proprietary data and analytics to profile family office characteristics. The information is intended solely for specific clients and is non-commercial in nature. It does not constitute investment research or advice. Certain services mentioned may be subject to legal restrictions in some jurisdictions. UBS and Campden Wealth Limited provided the information for informational purposes only and make no guarantees as to its accuracy or completeness.
The nuclear energy industry has lain stagnant for over 30 years and has suffered from missteps and perception issues.
Lightbridge is here to innovate and change the conversation. About: Lightbridge is a U.S. nuclear energy company based in McLean, Virginia with operations in Abu Dhabi, Moscow and London. The Company develops proprietary, proliferation resistant, next generation nuclear fuel technologies for current and future nuclear reactor systems. The Company also provides comprehensive advisory services for established and emerging nuclear programs based on a philosophy of transparency, non-proliferation, safety and operational excellence. Lightbridge's breakthrough fuel technology is establishing new global standards for safe and clean nuclear power and leading the way to a sustainable energy future. Lightbridge consultants provide integrated strategic advice and expertise across a range of disciplines including regulatory affairs, nuclear reactor procurement and deployment, reactor and fuel technology and international relations. The Company leverages those broad and integrated capabilities by offering its services to commercial entities and governments with a need to establish or expand nuclear industry capabilities and infrastructure.
Harris & Harris Group invests in transformative companies developing disruptive science and technology. It has a portfolio of 26 companies across various sectors including life sciences, electronics, and energy. Recent liquidity events from companies like Xradia that was acquired by Carl Zeiss have generated gains. The company aims to continue realizing value from its portfolio through partnerships and exits over the next few years to drive further growth.
The document discusses ChromaDex's forward-looking statements and FDA disclaimer. It then provides an overview of ChromaDex's mission to commercialize patented ingredient technologies, including nicotinamide riboside, pTeroPure, pterostilbene, and anthocyanins, in multi-billion dollar markets like dietary supplements and food and beverage. ChromaDex also has an established legacy business providing analytical testing services and natural products.
Oragenics is developing novel antibiotics and probiotics through synthetic biology collaborations. For antibiotics, they are focusing on lantibiotics, a class of naturally produced antibacterial peptides, to address the need for new antibiotics. Their lead compound MU1140 has shown efficacy against MRSA, VRE and C. difficile. For probiotics, they are engineering bacteria to deliver therapeutics locally in the oral cavity for diseases like canker sores and Behcet's disease. They also market the only patented probiotic for oral health called ProBiora3. Upcoming milestones include animal studies for MU1140 in 2014 and generating genetically modified probiotic prototypes in 2014-2015.
Spherix generates licensing revenues by investing in and acquiring patent assets, then monetizing those patents. In December 2013, Spherix acquired patents from Rockstar Consortium for $60 million in stock. Rockstar was formed by Apple, Microsoft, Sony, Blackberry and Ericsson to acquire the valuable Nortel patent portfolio. Spherix is asserting some of these patents against Cisco Systems and others and seeking licenses from data, voice, optical and access equipment companies. Management seeks to maximize patent value through litigation, licensing campaigns and new partnerships.
Angel investors provide seed funding and support for early stage ventures in exchange for equity, targeting higher returns than public markets; they are typically wealthy individuals who contribute time, experience and contacts in addition to money. Regulations require that angel investments follow securities laws to protect both entrepreneurs and investors, with legal oversight of offering documents and investor awareness of risks. As a wealth manager, one could suggest clients consider angel investing if they meet criteria like high income and net worth, entrepreneurial experience, and willingness to hold investments long-term in high-risk sectors like healthcare, software or biotech.
Building a High Value Patent Portfolio: Where Strength Meets QualityErik Oliver
Join Gene Quinn, patent attorney and founder of IPWatchdog.com and Erik Reeves, Founder of AcclaimIP and CTO of Anaqua, and Kent Richardson for a free webinar discussion on building a portfolio versus buying patents, identifying gaps in your patent coverage, and unlocking the secrets of your own patent portfolio to identify needs.
This document summarizes key findings from the 2019 Global Family Office Report. It was prepared by Campden Wealth Limited using proprietary data and analytics to profile family office characteristics. The information is intended solely for specific clients and is non-commercial in nature. It does not constitute investment research or advice. Certain services mentioned may be subject to legal restrictions in some jurisdictions. UBS and Campden Wealth Limited provided the information for informational purposes only and make no guarantees as to its accuracy or completeness.
The nuclear energy industry has lain stagnant for over 30 years and has suffered from missteps and perception issues.
Lightbridge is here to innovate and change the conversation. About: Lightbridge is a U.S. nuclear energy company based in McLean, Virginia with operations in Abu Dhabi, Moscow and London. The Company develops proprietary, proliferation resistant, next generation nuclear fuel technologies for current and future nuclear reactor systems. The Company also provides comprehensive advisory services for established and emerging nuclear programs based on a philosophy of transparency, non-proliferation, safety and operational excellence. Lightbridge's breakthrough fuel technology is establishing new global standards for safe and clean nuclear power and leading the way to a sustainable energy future. Lightbridge consultants provide integrated strategic advice and expertise across a range of disciplines including regulatory affairs, nuclear reactor procurement and deployment, reactor and fuel technology and international relations. The Company leverages those broad and integrated capabilities by offering its services to commercial entities and governments with a need to establish or expand nuclear industry capabilities and infrastructure.
Harris & Harris Group invests in transformative companies developing disruptive science and technology. It has a portfolio of 26 companies across various sectors including life sciences, electronics, and energy. Recent liquidity events from companies like Xradia that was acquired by Carl Zeiss have generated gains. The company aims to continue realizing value from its portfolio through partnerships and exits over the next few years to drive further growth.
The document discusses ChromaDex's forward-looking statements and FDA disclaimer. It then provides an overview of ChromaDex's mission to commercialize patented ingredient technologies, including nicotinamide riboside, pTeroPure, pterostilbene, and anthocyanins, in multi-billion dollar markets like dietary supplements and food and beverage. ChromaDex also has an established legacy business providing analytical testing services and natural products.
Oragenics is developing novel antibiotics and probiotics through synthetic biology collaborations. For antibiotics, they are focusing on lantibiotics, a class of naturally produced antibacterial peptides, to address the need for new antibiotics. Their lead compound MU1140 has shown efficacy against MRSA, VRE and C. difficile. For probiotics, they are engineering bacteria to deliver therapeutics locally in the oral cavity for diseases like canker sores and Behcet's disease. They also market the only patented probiotic for oral health called ProBiora3. Upcoming milestones include animal studies for MU1140 in 2014 and generating genetically modified probiotic prototypes in 2014-2015.
This document discusses Biocept, Inc., a commercial-stage cancer diagnostics company. It provides an overview of Biocept's liquid biopsy platform and tests, including OncoCEE and OncoCEE-BR, which measure circulating tumor cells. The document highlights Biocept's multi-faceted growth strategy including test menu expansion and increasing operational efficiency. It also introduces Biocept's executive team and discusses the large US market opportunity for cancer diagnostics.
Genius Brands International provides children's entertainment content across multiple platforms. It owns established brands like Baby Genius that have found success in television, online, mobile, and consumer products. The company aims to produce content that is both entertaining and enriching for kids. It has an experienced management team with decades of experience in the children's entertainment industry. Genius Brands sees opportunities to expand its brands internationally and introduce new content partnerships with figures like Warren Buffett, Thomas Edison, and Stan Lee.
This document provides an overview and disclaimer for a company called Abakan Inc. It discusses Abakan's technology for applying corrosion-resistant coatings to pipes, which could address a multi-billion dollar market opportunity. The document outlines Abakan's intellectual property portfolio, recent development milestones, potential customers in various industries, and the large market size for addressing the global corrosion problem. It disclaims any promises or warranties regarding investment details and requests that the information be kept confidential.
Lightbridge Corporation is an innovative nuclear fuel technology company that has developed a new metallic nuclear fuel design. The new fuel design provides several benefits including increased power output from existing reactors, improved safety, and reduced costs. Lightbridge has validated the technology and economics through third-party analyses and has an MOU with Babcock & Wilcox to develop a pilot fuel fabrication plant. The company also has a successful nuclear advisory services business and plans to license the new fuel technology globally. Lightbridge has an experienced management team and board of advisors with extensive experience in the nuclear industry.
Senesco Technologies is developing a gene regulation technology to treat cancer. They are running a Phase 1b/2a clinical trial of their lead product, SNS01-T, to treat B-cell cancers like multiple myeloma and lymphoma. Preclinical studies show SNS01-T significantly inhibits tumor growth and improves survival in mouse models of these cancers. The presentation provides an overview of Senesco's technology, clinical trial status, financial information, and development plans to advance SNS01-T and expand to additional cancer indications.
This document provides a business update from CombiMatrix Corporation for January 2014. It summarizes CombiMatrix's strategy of providing clinical support services in prenatal genetics, pediatric disorders, and oncology using microarray platforms, karyotyping, and FISH technologies. The management team is highlighted, including the President & CEO who has extensive experience in diagnostic sales. Recent highlights include a partnership with Sequenom to market prenatal microarray testing and third quarter 2013 financial results.
Energy Fuels is the nation's leading conventional uranium producer, supplying approximately 25% of the uranium produced in the U.S. (based on FY-2013 deliveries). The Company also has the capability to be a significant producer of vanadium. Energy Fuels owns and operates the White Mesa Mill, which is the only conventional uranium mill currently operating in the U.S. The mill is capable of processing 2,000 tons per day of uranium ore and producing up to 8 million lbs. of U3O8 per year (depending on ore grade).
Genius Brands International is a company focused on providing children's entertainment content with purpose for toddlers to tweens. It was created through the merger of A Squared Entertainment and Genius Brands. The document discusses Genius Brands' plans to grow its portfolio of animated properties like Baby Genius, Warren Buffett's Secret Millionaires Club, and new shows in partnership with Stan Lee and Martha Stewart. It aims to distribute this content across television, online, mobile and through a new streaming service, while supporting the content through consumer products licensing. The management team, including Andy and Amy Heyward, have decades of experience in the children's entertainment industry.
The document discusses Direct Insite, a company that provides cloud-based accounts payable and accounts receivable automation solutions. It notes that some statements may be forward-looking and discusses risks associated with such statements. It then provides an overview of Direct Insite's solutions, customers, and competitive advantages. Key points include its large network of over 450,000 suppliers and customers transacting over $130 billion annually, and its goal to achieve over 10% annual revenue growth through 2015 by expanding its sales force and introducing new products.
Opexa Therapeutics is developing Tcelna, a precision immunotherapy for the treatment of multiple sclerosis (MS). Tcelna consists of attenuated antigen-specific T-cell clones that are designed to program the immune system to target pathogenic myelin reactive T-cells (MRTC) that cause damage in MS. Opexa has completed enrollment in a Phase IIb clinical trial of Tcelna in secondary progressive MS (SPMS) and expects top-line data in mid-2016. The company has an option agreement with Merck for the development and commercialization of Tcelna in MS that could provide up to $220 million in payments if certain development and sales milestones are achieved.
Opexa Therapeutics is developing Tcelna, a precision immunotherapy for the treatment of secondary progressive multiple sclerosis (SPMS). Tcelna consists of attenuated myelin-reactive T-cell clones that are designed to program the immune system to target pathogenic myelin-reactive T-cells. Opexa has an ongoing Phase IIb clinical trial of Tcelna in SPMS and expects to complete enrollment in mid-2014, with top-line data expected in mid-2016. Opexa has an option agreement with Merck for the development and commercialization of Tcelna in MS that could provide up to $220 million in payments.
This document provides an overview of Big North Graphite Corp., a mining company exploring opportunities in Mexico and Canada. It discusses Big North's management team and board of directors, capital structure, and key investment highlights. Specifically, it outlines Big North's plans to accelerate re-starting operations at the historic Nuevo San Pedro Graphite Mine in Mexico, which produced amorphous graphite in the past. Big North acquired three past-producing graphite mines in Mexico and is working to resume production at Nuevo San Pedro.
This document provides an overview of Galectin Therapeutics, a clinical stage biopharmaceutical company targeting fibrotic diseases and cancer. It summarizes the company's focus on developing galectin inhibitors, proteins that are important in fibrosis and cancer. Specifically, it outlines Galectin's development program for non-alcoholic steatohepatitis (NASH), a fatty liver disease, including preclinical evidence, current Phase 1 clinical trial testing safety and pharmacokinetics, and plans for a Phase 2 trial to evaluate efficacy in reducing liver fibrosis.
Spherix generates licensing revenues by investing in and acquiring patent assets, then monetizing those patents. In December 2013, Spherix acquired patents from Rockstar Consortium for $60 million in stock, making Rockstar its largest shareholder. Spherix is asserting these patents, which relate to networking technologies such as virtual LAN tagging, against large companies like Cisco. The company is also pursuing other licensing agreements and legal cases to generate revenue from its patent portfolio.
Maris-Tech is a leading B2B provider of intelligent video transmission technology, founded by veterans of the Israel technology sector with extensive electrical engineering and imaging experience. Our products are designed to meet the growing demands of commercial and tactical applications, delivering high-performance, compact, low power and low latency solutions to companies worldwide, including leading electro-optical payload, RF datalink and unmanned platform manufacturers as well as defense, HLS, and communication companies.
Paul Ostergaard's presentation from the TechKnow Investor Roadshow series. Held in Gold Coast, Sydney and Melbourne Australia from 5th to 8th April 2016.
Waywaya Management & Consulting, LLC is managed by Princess Viray and serves as a referral partner connecting private family offices to financing opportunities for projects focused on environmental, social and governance goals. Fiscus Holdings, Inc. is an offshore holding company for five funds called Fiscus Funds that were co-founded by Princess Viray. Fiscus Treasury I, LLC is a US-based company managed by Princess Viray to support asset and capital acquisitions of Fiscus Holdings. The funds aim to digitally transform revenue from physical assets via smart contracts on the blockchain.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
Norwood CEO, Paul Ostergaard delivers an exciting presentation on our latest product updates and important commercial announcements at the TechKnow Invest Roadshow 2017.
Finjan offers investors a diversified and unique vehicle for investing in cybersecurity related intellectual property-backed technologies under the guidance of a proven team.
Stark Networks HK
Advisory and Consulting for Property Investment Technology Projects
Sustainability * Energy Efficiency
Stark Networks HK :: Advisory and Business Consultancy
Structured Financing in conjunction with Energy :: Working with Corporations in Project Partnerships
IntelGenX Investor Presentation June 5, 2017ItelGenx
- IntelGenx Corp. is a drug delivery company focused on oral thin film technologies.
- They have developed a proprietary drug delivery platform called Tri-Layer technology to improve the speed and efficiency of drug absorption through the oral mucosa.
- The presentation provides an overview of IntelGenx's management team, facilities, product pipeline, and financial information to investors considering an investment in the company.
This document discusses Biocept, Inc., a commercial-stage cancer diagnostics company. It provides an overview of Biocept's liquid biopsy platform and tests, including OncoCEE and OncoCEE-BR, which measure circulating tumor cells. The document highlights Biocept's multi-faceted growth strategy including test menu expansion and increasing operational efficiency. It also introduces Biocept's executive team and discusses the large US market opportunity for cancer diagnostics.
Genius Brands International provides children's entertainment content across multiple platforms. It owns established brands like Baby Genius that have found success in television, online, mobile, and consumer products. The company aims to produce content that is both entertaining and enriching for kids. It has an experienced management team with decades of experience in the children's entertainment industry. Genius Brands sees opportunities to expand its brands internationally and introduce new content partnerships with figures like Warren Buffett, Thomas Edison, and Stan Lee.
This document provides an overview and disclaimer for a company called Abakan Inc. It discusses Abakan's technology for applying corrosion-resistant coatings to pipes, which could address a multi-billion dollar market opportunity. The document outlines Abakan's intellectual property portfolio, recent development milestones, potential customers in various industries, and the large market size for addressing the global corrosion problem. It disclaims any promises or warranties regarding investment details and requests that the information be kept confidential.
Lightbridge Corporation is an innovative nuclear fuel technology company that has developed a new metallic nuclear fuel design. The new fuel design provides several benefits including increased power output from existing reactors, improved safety, and reduced costs. Lightbridge has validated the technology and economics through third-party analyses and has an MOU with Babcock & Wilcox to develop a pilot fuel fabrication plant. The company also has a successful nuclear advisory services business and plans to license the new fuel technology globally. Lightbridge has an experienced management team and board of advisors with extensive experience in the nuclear industry.
Senesco Technologies is developing a gene regulation technology to treat cancer. They are running a Phase 1b/2a clinical trial of their lead product, SNS01-T, to treat B-cell cancers like multiple myeloma and lymphoma. Preclinical studies show SNS01-T significantly inhibits tumor growth and improves survival in mouse models of these cancers. The presentation provides an overview of Senesco's technology, clinical trial status, financial information, and development plans to advance SNS01-T and expand to additional cancer indications.
This document provides a business update from CombiMatrix Corporation for January 2014. It summarizes CombiMatrix's strategy of providing clinical support services in prenatal genetics, pediatric disorders, and oncology using microarray platforms, karyotyping, and FISH technologies. The management team is highlighted, including the President & CEO who has extensive experience in diagnostic sales. Recent highlights include a partnership with Sequenom to market prenatal microarray testing and third quarter 2013 financial results.
Energy Fuels is the nation's leading conventional uranium producer, supplying approximately 25% of the uranium produced in the U.S. (based on FY-2013 deliveries). The Company also has the capability to be a significant producer of vanadium. Energy Fuels owns and operates the White Mesa Mill, which is the only conventional uranium mill currently operating in the U.S. The mill is capable of processing 2,000 tons per day of uranium ore and producing up to 8 million lbs. of U3O8 per year (depending on ore grade).
Genius Brands International is a company focused on providing children's entertainment content with purpose for toddlers to tweens. It was created through the merger of A Squared Entertainment and Genius Brands. The document discusses Genius Brands' plans to grow its portfolio of animated properties like Baby Genius, Warren Buffett's Secret Millionaires Club, and new shows in partnership with Stan Lee and Martha Stewart. It aims to distribute this content across television, online, mobile and through a new streaming service, while supporting the content through consumer products licensing. The management team, including Andy and Amy Heyward, have decades of experience in the children's entertainment industry.
The document discusses Direct Insite, a company that provides cloud-based accounts payable and accounts receivable automation solutions. It notes that some statements may be forward-looking and discusses risks associated with such statements. It then provides an overview of Direct Insite's solutions, customers, and competitive advantages. Key points include its large network of over 450,000 suppliers and customers transacting over $130 billion annually, and its goal to achieve over 10% annual revenue growth through 2015 by expanding its sales force and introducing new products.
Opexa Therapeutics is developing Tcelna, a precision immunotherapy for the treatment of multiple sclerosis (MS). Tcelna consists of attenuated antigen-specific T-cell clones that are designed to program the immune system to target pathogenic myelin reactive T-cells (MRTC) that cause damage in MS. Opexa has completed enrollment in a Phase IIb clinical trial of Tcelna in secondary progressive MS (SPMS) and expects top-line data in mid-2016. The company has an option agreement with Merck for the development and commercialization of Tcelna in MS that could provide up to $220 million in payments if certain development and sales milestones are achieved.
Opexa Therapeutics is developing Tcelna, a precision immunotherapy for the treatment of secondary progressive multiple sclerosis (SPMS). Tcelna consists of attenuated myelin-reactive T-cell clones that are designed to program the immune system to target pathogenic myelin-reactive T-cells. Opexa has an ongoing Phase IIb clinical trial of Tcelna in SPMS and expects to complete enrollment in mid-2014, with top-line data expected in mid-2016. Opexa has an option agreement with Merck for the development and commercialization of Tcelna in MS that could provide up to $220 million in payments.
This document provides an overview of Big North Graphite Corp., a mining company exploring opportunities in Mexico and Canada. It discusses Big North's management team and board of directors, capital structure, and key investment highlights. Specifically, it outlines Big North's plans to accelerate re-starting operations at the historic Nuevo San Pedro Graphite Mine in Mexico, which produced amorphous graphite in the past. Big North acquired three past-producing graphite mines in Mexico and is working to resume production at Nuevo San Pedro.
This document provides an overview of Galectin Therapeutics, a clinical stage biopharmaceutical company targeting fibrotic diseases and cancer. It summarizes the company's focus on developing galectin inhibitors, proteins that are important in fibrosis and cancer. Specifically, it outlines Galectin's development program for non-alcoholic steatohepatitis (NASH), a fatty liver disease, including preclinical evidence, current Phase 1 clinical trial testing safety and pharmacokinetics, and plans for a Phase 2 trial to evaluate efficacy in reducing liver fibrosis.
Spherix generates licensing revenues by investing in and acquiring patent assets, then monetizing those patents. In December 2013, Spherix acquired patents from Rockstar Consortium for $60 million in stock, making Rockstar its largest shareholder. Spherix is asserting these patents, which relate to networking technologies such as virtual LAN tagging, against large companies like Cisco. The company is also pursuing other licensing agreements and legal cases to generate revenue from its patent portfolio.
Maris-Tech is a leading B2B provider of intelligent video transmission technology, founded by veterans of the Israel technology sector with extensive electrical engineering and imaging experience. Our products are designed to meet the growing demands of commercial and tactical applications, delivering high-performance, compact, low power and low latency solutions to companies worldwide, including leading electro-optical payload, RF datalink and unmanned platform manufacturers as well as defense, HLS, and communication companies.
Paul Ostergaard's presentation from the TechKnow Investor Roadshow series. Held in Gold Coast, Sydney and Melbourne Australia from 5th to 8th April 2016.
Waywaya Management & Consulting, LLC is managed by Princess Viray and serves as a referral partner connecting private family offices to financing opportunities for projects focused on environmental, social and governance goals. Fiscus Holdings, Inc. is an offshore holding company for five funds called Fiscus Funds that were co-founded by Princess Viray. Fiscus Treasury I, LLC is a US-based company managed by Princess Viray to support asset and capital acquisitions of Fiscus Holdings. The funds aim to digitally transform revenue from physical assets via smart contracts on the blockchain.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
Norwood CEO, Paul Ostergaard delivers an exciting presentation on our latest product updates and important commercial announcements at the TechKnow Invest Roadshow 2017.
Finjan offers investors a diversified and unique vehicle for investing in cybersecurity related intellectual property-backed technologies under the guidance of a proven team.
Stark Networks HK
Advisory and Consulting for Property Investment Technology Projects
Sustainability * Energy Efficiency
Stark Networks HK :: Advisory and Business Consultancy
Structured Financing in conjunction with Energy :: Working with Corporations in Project Partnerships
IntelGenX Investor Presentation June 5, 2017ItelGenx
- IntelGenx Corp. is a drug delivery company focused on oral thin film technologies.
- They have developed a proprietary drug delivery platform called Tri-Layer technology to improve the speed and efficiency of drug absorption through the oral mucosa.
- The presentation provides an overview of IntelGenx's management team, facilities, product pipeline, and financial information to investors considering an investment in the company.
This document provides information on AIA Capital Technology Fund, L.L.C., a long/short technology hedge fund. It discloses various risks and that this is not an offer to sell investments. The fund will utilize five investment strategies focused on technology companies, including new issue equities and debt securities. It is targeted at institutional investors like pension funds. The management team has over 50 years of combined experience. The goal is to achieve $50 million in assets under management by utilizing proprietary strategies and risk management processes.
Abaxx Technologies Inc. (ABXX:CN) is traded on Canada's NEO Stock Exchange.
Abaxx Technologies Inc. is a development stage financial technology business developing software tools which enable commodity traders and finance professionals to communicate, manage risk, and transact faster and more securely.
Abaxx Investor Presentation January 2021Paris Golab
This corporate presentation provides an overview of Abaxx Technologies Inc., a full-stack financial technology company developing a regulated commodity futures exchange in Singapore. Abaxx's mission is to improve price signals in markets for the energy transition by creating new benchmarks for trading natural resource commodities based on environmental, social, and governance factors. The presentation outlines Abaxx's business segments, leadership team, and opportunities in the liquefied natural gas market as the exchange's initial focus as the LNG market transitions towards short-term trading.
Access and control – “What you need when you need it”.
Shared outlook and mindset.
No jargon. Access to principles. Honest and direct.
Decisive, logical – the people and the systems and analysis that supports them.
Faro Technologies is a leader in 3D measurement technologies with strong products and customer value propositions. However, the company has failed to deliver shareholder returns due to poor execution, elevated growth expectations, and a bloated cost structure. Avasar Partners believes Faro is significantly undervalued at its current price given its assets and market opportunity. Avasar's thesis is that with the right leadership changes, strategic focus on profitable growth, and accountability, Faro can improve operations and deliver shareholder returns of $49 per share by the end of 2016 and $86 per share by 2018 through achieving appropriate revenue, cost, and productivity targets.
1) The document is a confidential information package from Atlas FinTech Holdings Corp describing their business model and vision.
2) Atlas aims to provide specialized banking, clearing, and settlement services for financial institutions in Latin America through an integrated platform and innovative proprietary technology solutions.
3) The management team believes this will provide a unique full-service solution to clients in a market with significant opportunity due to the exit of large global banks from the region.
Draganfly has been a leader in the professional drone industry for more than 20 years, supporting clients with enterprise drone solutions, contract engineering services, custom software, professional unmanned aerial vehicle (UAV) services, and more. From public safety to pop culture, Draganfly has shaped not just the UAV industry, but the way people around the world work and live. Breaking ground with international firsts, Draganfly has a legacy of leading the professional drone industry, including releasing the first commercialized quadrotor UAV in 1999 and releasing the first multirotor UAV with an integrated camera system in 2001. In 2013, Draganflyer was credited as the world’s first small unmanned aerial system (sUAS) to save a person’s life, and in 2016, Draganfly became the first company to have multiple UAV systems deemed Transport Canada Compliant.
TrustOptix was formed in 2013 to create an authentication and anti-counterfeiting system for the $8 billion counterfeit market. It uses nanoscale circuitry embedded in materials to authenticate products throughout the supply chain. It has received a state grant and is seeking a $5 million Series A investment to continue prototype development, equipment acquisition, and manufacturing. The company aims to provide solutions to counterfeiting issues faced by the defense, art, and other industries.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
Starve Ups Membership Company Arcimoto is Going Public★ MIKE SHUR
Arcimoto filed its public Form 1-A offering circular this afternoon with the SEC. This comprehensive document tells the story of the company in detail, and outlines its production and growth plans. If you’re not quite ready to chew through 120 pages of dense company documentation, you can see the 5-minute video version above here: http://bit.ly/2t4K8Di
Finjan is a technology company committed to investing in innovation, advancing the development of new technologies while promoting the value of IP rights.
Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...RedChip Companies, Inc.
This document provides an overview of Big North Graphite Corp., a mining company exploring graphite opportunities in Mexico and Canada. It summarizes the management team's experience, the capital structure including shares outstanding and warrants, and key investment highlights. Specifically, it notes Big North is currently selling amorphous graphite in Mexico and aims to restart near-term flake graphite production at its recently acquired El Tejon Flake Graphite Mine and Mill in Oaxaca, Mexico, which was previously operational until 2002. A cautionary note also indicates forward-looking statements may materially differ from expectations.
“The Coin Tree is a cloud-based storage, insurance, and payment processing platform for bitcoin that leverages cutting edge transactional security to serve the ever expanding virtual currency community."
StarStream Entertainment is a theatrical motion picture production and financing company focused on producing and financing edgy, high quality motion pictures with strong cast and lean budgets for a commercial audience.
StarStream Entertainment is a theatrical motion picture production and financing company focused on producing and financing edgy, high quality motion pictures with strong cast and lean budgets for a commercial audience.
StarStream Entertainment aims to be a theatrical motion picture production and financing company focused on producing edgy, high quality films with strong casts and lean budgets. It mitigates risk through fiscal precision by financing projects once they are fully developed and ready to produce, offering investors a quicker return. Recent successful films include Lee Daniels' The Butler, Life of Crime, and Life After Beth.
Cancer Genetics provides personalized cancer treatment through molecular diagnostic testing. They have launched 6 proprietary diagnostic products targeting hematological and urogenital cancers. Their tests help determine cancer type and prognosis, guiding treatment selection. Recent acquisitions expand their capabilities and access to new markets in India. Their business model provides clinical testing services to oncologists and biopharma partnerships to support drug development.
- Bitcoin Shop is one of the first publicly traded companies focused on the virtual currency ecosystem. It operates an ecommerce platform that accepts bitcoin and other cryptocurrencies as payment.
- The company is developing its BTCS 2.0 platform to expand its product offerings and vendor base. It aims to build a virtual currency ecosystem through ecommerce.
- Bitcoin Shop has a experienced management team with expertise in capital markets, technology, and the virtual currency industry. It plans to grow its customer base and monetize through additional service offerings.
InterCloud Systems provides cloud-centric solutions and services to enterprises and service providers. Their two main business focus areas are Software Defined Enterprise and Cloud to Cloud Mobility. They help customers modernize infrastructure, develop cloud strategies, and deliver cloud-centric IT visions aligned to business value. InterCloud partners with major cloud platform and solution providers like VMware, OpenStack, and CloudStack.
This presentation provides an overview of SANUWAVE Health Inc., a regenerative medicine company developing non-invasive biological response activation devices. SANUWAVE's lead product, dermaPACE, is in a Phase III FDA trial for treating diabetic foot ulcers and has the potential for approval in 2015 pending positive results. DermaPACE offers a lower-cost, non-invasive alternative to existing wound therapies. If approved, dermaPACE could address the large diabetic foot ulcer market and be expanded to other applications. SANUWAVE completed a $9.3 million capital raise to fund the dermaPACE trial and has 38 patents covering its shockwave technology platform.
StationDigital is a digital media and ecommerce platform that allows users to stream or access any media and purchase digital and physical goods from any device. It has grown rapidly since its public beta launch in 2013, achieving over 1.3 million mobile users. The presentation outlines StationDigital's mission and growth strategy, competitive advantages over other media companies, and large market opportunity in digital media and ecommerce. It argues that StationDigital is well positioned for continued growth and market share capture.
DRONE Aviation Corp (DRNE) was formed in April 2014 to penetrate the rapidly growing Unmanned Aerial Systems (UAS) business in U.S. and abroad for government and commercial customers.
DRNE’s mission is to aggressively penetrate the expanding Drone market with our unique Tethered Drones, which are currently being fielded to the U.S. Department of Defense and State and Local municipalities.
DRNE owns and operates Florida-based Lighter Than Air Systems Corp (LTAS), a developer and supplier of unique and specialized aerial solutions to the U.S. Government, State municipalities, and commercial entities.
InterCloud Systems Incorporated is a single - source provider of end - to - end IT technology and telecom solutions to the ent erprise, service provider, and g overnment markets through “Cloud Platforms” and professional services. “Cloud Comput ing”, is defined as the use of computing resources (compute, NTK, Storage) that are delivered as a managed service over a network. InterCloud offers its service provider custo mers the ability to utilize “cloud” solutions inside their existing network footp rint as well as in a “white label environment” so it can offer a suite of cloud products under their own brand, delivered over the broadband services it presently sell s . ICLD’s cloud services include infrastructure as a service (IaaS), platform as a servi ce (PaaS), and software as a service (SaaS) .
This document provides an overview of Actinium Pharmaceuticals, Inc. and summarizes their proprietary alpha particle immunotherapy technology and product pipeline. Key points include:
1) Actinium has a pipeline of targeted radiotherapy candidates using alpha emitters to treat various blood cancers. Their lead candidate, Iomab-B, is being developed for conditioning blood cancer patients prior to bone marrow transplant.
2) Iomab-B has shown promising results in clinical trials, successfully preparing older refractory AML patients for transplant who otherwise would not be eligible. Actinium has FDA agreement to advance Iomab-B into a Phase III registration trial.
3) Actinium has a proprietary technology
Richfield Oil & Gas Company (OTCQX: ROIL) is an independent exploration and production company headquartered in Salt Lake City, Utah. The Company’s current oil production flows from wells in fields located in Kansas and Wyoming. In addition to several thousand acres in Kansas, Richfield also owns strategically-located exploratory leases in central Utah on trend to major oil discoveries.
NeoStem, Inc. (“NeoStem” or the “Company”), a biopharmaceutical company, is capitalizing on the paradigm shift occurring in medicine by engaging in the development and manufacture of cellular therapies for oncology, immunology, and regenerative medicines in the United States. The Company anticipates that cell therapy will play a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society.
American Water provides water and wastewater services to approximately 14 million people in 16 states, has a market capitalization of $8.6 billion, and seeks to continue growing its regulated water business through capital investments and acquisitions while also expanding its complementary market-based business lines. The company has delivered strong total shareholder returns since its 2008 IPO and maintains a transparent dividend policy aimed at increasing its dividend in line with normalized earnings per share growth.
Exeo Entertainment, Inc. is a manufacturing company concentrating on developing innovative products that fill a clearly defined need in today’s interactive entertainment industry. Featured products include the Zaaz™ smart TV keyboards, Patented Psyko Krypton™ 5.1 gaming headphones, Krankz Bluetooth music headphones, an Android® based portable gaming system, and the Extreme Gamer® -the world’s first multi–disc game changer.
Direct Insite (“DIRI”) provides cloud-based, ERP-agnostic solutions that automate Accounts Payable (AP) and Accounts Receivable (AR) invoice processes for Global 3000 companies. Their solutions include invoice validation, order matching, consolidation, dispute handling and e-payment processing. DIRI helps clients eliminate manual processes and costs associated with doing everything on paper. By migrating from paper to electronic, DIRI can reduce transactions costs 50-70% and reduce time by 80%. Current clients include Siemens, HP, IBM, Saint-Gobain, Shell Oil, and Hyatt with a Global vendor network of 350,000+ suppliers.
Lattice Incorporated (“Lattice” or the “Company”), founded in 1973, provides secure communications and information technology, specializing in deploying advanced technology and services to create innovative, cost - effective solutions for the Company’s global customers. The Company provides both wholesale and direct services to correctional facilities and their service providers in the U.S., Canada and Europe. Expansion of Lattice’s direct and wholesale services, including increased techno logy equipment and software sales to wholesale customers, is expected to drive revenue growth and increased margins in the quarters ahead
Quadrant 4 Systems Corporation is a leading provider in of health exchange platforms, innovative software products and proprietary SMAC (social media, mobility, analytics and cloud computing) solutions to enterprise clients in Retail and Manufacturing, Media and Publishing, Financial Services and Health Care sectors.
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN CHART KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART INDIA MATKA KALYAN SATTA MATKA 420 INDIAN MATKA SATTA KING MATKA FIX JODI FIX FIX FIX SATTA NAMBAR MATKA INDIA SATTA BATTA
The Most Inspiring Entrepreneurs to Follow in 2024.pdfthesiliconleaders
In a world where the potential of youth innovation remains vastly untouched, there emerges a guiding light in the form of Norm Goldstein, the Founder and CEO of EduNetwork Partners. His dedication to this cause has earned him recognition as a Congressional Leadership Award recipient.
Unlocking WhatsApp Marketing with HubSpot: Integrating Messaging into Your Ma...Niswey
50 million companies worldwide leverage WhatsApp as a key marketing channel. You may have considered adding it to your marketing mix, or probably already driving impressive conversions with WhatsApp.
But wait. What happens when you fully integrate your WhatsApp campaigns with HubSpot?
That's exactly what we explored in this session.
We take a look at everything that you need to know in order to deploy effective WhatsApp marketing strategies, and integrate it with your buyer journey in HubSpot. From technical requirements to innovative campaign strategies, to advanced campaign reporting - we discuss all that and more, to leverage WhatsApp for maximum impact. Check out more details about the event here https://events.hubspot.com/events/details/hubspot-new-delhi-presents-unlocking-whatsapp-marketing-with-hubspot-integrating-messaging-into-your-marketing-strategy/
Tired of chasing down expiring contracts and drowning in paperwork? Mastering contract management can significantly enhance your business efficiency and productivity. This guide unveils expert secrets to streamline your contract management process. Learn how to save time, minimize risk, and achieve effortless contract management.
AI Transformation Playbook: Thinking AI-First for Your BusinessArijit Dutta
I dive into how businesses can stay competitive by integrating AI into their core processes. From identifying the right approach to building collaborative teams and recognizing common pitfalls, this guide has got you covered. AI transformation is a journey, and this playbook is here to help you navigate it successfully.
Efficient PHP Development Solutions for Dynamic Web ApplicationsHarwinder Singh
Unlock the full potential of your web projects with our expert PHP development solutions. From robust backend systems to dynamic front-end interfaces, we deliver scalable, secure, and high-performance applications tailored to your needs. Trust our skilled team to transform your ideas into reality with custom PHP programming, ensuring seamless functionality and a superior user experience.
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN CHART KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART
NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...BBPMedia1
Nathalie zal delen hoe DEI en ESG een fundamentele rol kunnen spelen in je merkstrategie en je de juiste aansluiting kan creëren met je doelgroep. Door middel van voorbeelden en simpele handvatten toont ze hoe dit in jouw organisatie toegepast kan worden.
The APCO Geopolitical Radar - Q3 2024 The Global Operating Environment for Bu...APCO
The Radar reflects input from APCO’s teams located around the world. It distils a host of interconnected events and trends into insights to inform operational and strategic decisions. Issues covered in this edition include:
Presentation by Herman Kienhuis (Curiosity VC) on Investing in AI for ABS Alu...Herman Kienhuis
Presentation by Herman Kienhuis (Curiosity VC) on developments in AI, the venture capital investment landscape and Curiosity VC's approach to investing, at the alumni event of Amsterdam Business School (University of Amsterdam) on June 13, 2024 in Amsterdam.
2. LEGAL DISCLAIMER
This presentation and other written or oral statements made from time to time by representatives of Spherix (“NSH”) contain “forward-looking statements”
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements reflect the current view about future events. Statements that are not historical in nature, and which may be identified by the use of words like
“expects,” “assumes,” “projects,” “anticipates,” “estimates,” “we believe,” “could be,” "future" or the negative of these terms and other words of similar
meaning, are forward-looking statements. Forward-looking statements are based on management’s current expectations and assumptions regarding our
business, the economy and other future conditions and are subject to inherent risks, uncertainties and changes of circumstances that are difficult to predict
and may cause actual results to differ materially from those contemplated or expressed. Should one or more of these risks or uncertainties materialize, or
should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or
planned.
Important factors that could cause actual results to differ materially from those in the forward looking statements include: a continued decline in general
economic conditions nationally and internationally; decreased demand for our products and services; market acceptance of our products; the ability to
protect our intellectual property rights; impact of any litigation or infringement actions brought against us; competition from other providers and products;
risks in product development; inability to raise capital to fund continuing operations; changes in government regulation, the ability to complete customer
transactions and capital raising transactions.
Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot
guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United
States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.
Forecast
All Forecasts are provided by management in this presentation and are based on information available to us at this time and management expects that
internal projections and expectations may change over time. In addition, the forecasts are entirely on management’s best estimate of our future financial
performance given our current contracts, current backlog of opportunities and conversations with new and existing customers about our products.
Information
All information contained in or disclosed in this document, hereinafter called “ Information”, is proprietary to us. By accepting the material, the recipient
agrees that this Information will be held in confidence, and will not be reproduced or transferred, either in whole or in pare, without our prior written
permission.
The recipient agrees that it will not disclose to any third party or use any Information disclosed to it by us except when expressly permitted in writing by us.
Recipient also agrees that it will take all reasonable measures to maintain the ity of all Information in its possession or control.
This overview is delivered solely as reference material with respect to our company. This document shall not constitute an offer to sell or the solicitation of an
offer to buy securities in our company in any jurisdiction. The information herein is based on data obtained from sources believed to be reliable.
SPHERIX
LEADING INNOVATION THROUGH INVENTION
2
3. OVERVIEW
Spherix generates licensing revenues by investing in and acquiring patent
rights and assets via operating subsidiaries.
Symbol
SPEX
Exchange:
NASDAQ
Shares Outstanding:
16,361,584
Debt:
0
Auditor:
MARCUM
Corporate HQ:
NEW YORK
Average Volume three month:
224,000
SPHERIX
LEADING INNOVATION THROUGH INVENTION
3
4. OVERVIEW
Through its experienced management team and extensive network, Spherix
sources high-quality patent portfolios.
• Spherix CEO has successfully monetized patents through a wide
variety of monetization methods, including asset restructuring and
licensing brought against companies such as Cisco, Broadcom,
Nokia, Ericsson, Tellabs, and Alcatel-Lucent.
• Our due diligence has secured excellent results in
acquiring premium patent assets.
• Spherix carries no debt.
• Settlements from its initial licensing campaign generated in 3
months.
SPHERIX
LEADING INNOVATION THROUGH INVENTION
4
5. FOR INVESTORS AND INNOVATORS
Spherix strives to be a true partner.
•
The Spherix Technology Advisory Board was established by the company to
provide compensation to inventors of patent portfolios acquired by Spherix, so
that the inventors can share in proceeds related to the commercialization of
their ideas. Spherix’s philosophy of protecting inventors and supporting
innovation is a core belief of our company and its management.
•
Expert Analysis and Structuring.
•
Transforming undervalued, underutilized assets into revenues.
•
Patent assets are often hidden balance sheet “gems” with no value on the
balance sheet of the owning company.
•
We creatively structure risk and reward value sharing arrangements that
provide financial support, technical expertise and analysis.
•
We bolster investor rights and remedies.
•
LEADING INNOVATION THROUGH INVENTION
SPHERIX
5
6. IP MONETIZATION CLASS
Growth
• Massive market of underutilized IP.
Upside
• An appropriately structured IP portfolio provides income and the
potential for outsize returns.
Non Correlation
• IP value does not track the market and can capture past
commercial activity, making revenues countercyclical.
Portfolio Diversification
• IP is a hedge against exposure to technology companies.
SPHERIX
LEADING INNOVATION THROUGH INVENTION
6
7. VALUATION OF PUBLICLY TRADED IP COMPANIES
VirnetX:
$1.05 Billion
IP was acquired
Acacia Research:
$1.1 Billion
Licensor of IP
Vringo:
$260 Million
IP was acquired
RPX Patent:
$831 Million
Licensor of IP
Pendrell:
$502 Million
IP was acquired
Unwired Planet:
$165 Million
IP was acquired
InterDigital:
$1. 53 Billion
Technology Based IP
Tessara:
$998 Million
Technology Based IP
ParkerVision:
$324 Million
Technology Based IP
SPHERIX
LEADING INNOVATION THROUGH INVENTION
7
8. BUSINESS MODEL
Ability to Source and Monetize
New Portfolios
Ability to Produce Long Term
Revenue Stream
•
•
•
Unique ability to source new portfolios
CEO has a successful track record
Exhaustive due diligence and licensing
•
Licensing campaigns form independent revenue
streams
Low overhead
Multiple on-going licensing campaigns enhances
operating margins
•
•
224 Patents
Assets and Revenue Diversification
•
•
•
Highly Scalable Business
Model
•
•
Management’s experience allows for extensive deal
flow to high-quality patent assets across various sectors
Performing assets provide immediate revenue
generation
Sizable and diverse portfolio and numerous licensing
campaigns give rise to consistent revenue opportunity
Additional patent assets and licensing campaigns do
not require significant increase in overhead
Business model has excellent operating leverage
SPHERIX
LEADING INNOVATION THROUGH INVENTION
8
10. REVENUE DIVERSIFICATION
• Patent agnostic portfolios cover various industries.
• Concurrent licensing campaigns over multiple patent portfolios.
• Our licensing campaigns can create reliable occurrence of revenue
events.
• Portfolio diversification minimizes high risk from high concentrated
holdings.
• Management open to opportunistic licensing campaigns with green
field outcome.
SPHERIX
LEADING INNOVATION THROUGH INVENTION
10
12. •
Spherix has entered into a
relationship with the Rockstar
Consortium. Rockstar is jointly owned
by Apple, Blackberry, Sony,
Microsoft, Erricson and EMC.
SPHERIX
• Through this relationship, Spherix has
secured a suite of patents which is
the basis of Spherix’s most recent
lawsuit against both Uniden and
Vtech.
• Rockstar is an equity stakeholder in
Spherix and the companies both
continue to work together to optimize
their relationship, through consulting
services and other possible
Intellectual Property transactions.
LEADING INNOVATION THROUGH INVENTION
SPHERIX
12
13. ASSETS AND LICENSING CAMPAIGNS
SPHERIX OWNS OVER 200 PATENTS
Active Infringement Lawsuits:
• T-Mobil - geolocation patent
• Uniden - cordless telephony
patents
• VTech - cordless telephony
patents
•
First licensing campaign commenced in April 2013.
•
2 licensing settlements announced in the first 3
months.
Partnership with the Rockstar Consortium
• Owns over 4000 patents based on Nortel Networks groundbreaking
innovation engine.
• Manages highly valued patent portfolio relevant to all telecom and
high tech services and devices.
SPHERIX
LEADING INNOVATION THROUGH INVENTION
13
14. HARRIS PATENT PORTFOLIO
Acquired Harris Portfolio
222 patents
Harris Technology
Leader in defense communications and electronics
Average patent includes:
3.96 independent claims
25.41 total claims
Average expiration of 2021
Expertise includes:
Numerous technologies:
Antennas
Electro-optics
Signal processing
Microelectronics
Image processing
Cyber systems
Information systems
Mechatronics
15 years of R&D: 1993-2007
45 technology classifications
300 unique inventors
SPHERIX
14
LEADING INNOVATION THROUGH INVENTION
15. HARRIS PATENT PORTFOLIO
U.S. Patent No. 5,719,584
“System and Method for Determining the Geolocation of a Transmitter”
Geo-location technology of cell phones.
Employed by many cell phone carriers.
Retained litigation counsel.
Filed suit against T-Mobile.
Anticipate additional licensing activities
on this technology in the near future.
SPHERIX
15
LEADING INNOVATION THROUGH INVENTION
16. HARRIS PATENT PORTFOLIO
Spherix filed lawsuit against T-Mobile
T-Mobile provides service to approximately 34.0 million customers through its network.
Investigating similar infringement by other wireless carriers using geolocation.
SPHERIX
LEADING INNOVATION THROUGH INVENTION
16
17. COMPUFILL PATENT PORTFOLIO
Acquired Compufill Portfolio
April 5, 2013 (via North South)
The portfolio relates to the automatic refilling of
prescriptions through the use of your telephone.
•
Portfolio is litigation tested
•
Assets already generating revenue for Spherix.
•
Enforcement actions file.
•
Approximately fifty (50) potential.
•
Additional infringers on 2 patents.
SPHERIX
LEADING INNOVATION THROUGH INVENTION
17
18. CORDLESS PHONE PATENT PATENT PORTFOLIO ACQUIRED FROM ROCKSTAR
Independent patent rating company, (Pantros IP) awards a high
rating of 750 after the most recent acquisition of the Rockstar
patents. This high rating indicates strong, high value patents that we
intend to monetize through our IP claims against Uniden, Vtech, and
others.
SPHERIX
LEADING INNOVATION THROUGH INVENTION
18
19. LEGAL FILINGS
VTech
Filed September 3, 2013
• The patents included in the suit cover many models of cordless telephones.
• VTech claims to be the world's largest cordless telephone producer, including the
production of phones for AT&T (Vtech 2011 annual report).
• Vtech reported to have over $2.6 billion of revenues during the claimed
infringement period.
• VTech cordless phones sold at Wal-Mart, Best Buy, Circuit City, Costco, Office
Depot, Staples, Target and other locations.
• Patents at issue invented by former Nortel employees working in the U.S. and
Canada.
• Many of these inventors are now working with Spherix.
SPHERIX
LEADING INNOVATION THROUGH INVENTION
19
20. LEGAL FILINGS
Uniden
Filed September 9, 2013
• The patents included in the suit cover many models of cordless telephones.
• Original inventors are on the Spherix board of advisors.
• Patents acquired in a partnership agreement with Rockstar.
Key Product line: DECT 6.0 Cordless Telephones
•
Single line phones with or without digital answering system.
•
Multi line phones with or without digital answering system.
•
Corded/Cordless systems.
•
Amplified Big Button.
•
World’s 1st waterproof floating handset.
•
MultiRange long range phones.
Uniden America Corporation, the North American subsidiary of Japan-based Uniden
Corporation, manufactures and markets wireless consumer electronic products. Based
in Fort Worth, Texas, Uniden sells its products through dealers and distributors
throughout North, Central and South America.
SPHERIX
LEADING INNOVATION THROUGH INVENTION
20
21. MANAGEMENT
Anthony Hayes, President & CEO
Mr. Hayes has successfully monetized patents through all known
monetization methods, including portfolio optimization and licensing
brought against companies such as Cisco, Broadcom, Nokia, Ericsson,
Tellabs, and Alcatel-Lucent. Mr. Hayes is also a consultant to several IP
licensing companies. Mr. Hayes has received national recognition during his
legal career, including: Special recognition by President George W. Bush,
American Board of Trial Advocates Young Lawyer of the Year; and City of
Columbia "20 Under 40." Mr. Hayes earned a Juris Doctor from Tulane
University School of Law in 1995 and prior to law school, Mr. Hayes worked
on the floor of the NYMEX on Wall Street. He also has his B.A. in Economics
from Mary Washington College in Fredericksburg, Virginia.
SPHERIX
LEADING INNOVATION THROUGH INVENTION
21
22. MANAGEMENT
Darrell Dotson, Licensing & Litigation Consultant
Mr. Dotson attended Texas A&M University in College Station, Texas and
received a B.S. in Biology in 1988 and a second B.S. Degree in Zoology in 1989.
After graduating from college, he attended The University of Texas Health/
Science Center Graduate School of Biomedical Sciences in Houston, Texas,
where he received his Ph.D. in Biochemistry and Molecular Biology in 1994. After
graduate school, he attended University of Houston Law Center where he
earned a J.D. in 1997.
He is licensed to practice in all state courts in Texas and before the United
States Patent and Trademark Office. He is also licensed in the United States
District Courts for the Eastern and Southern Districts of Texas.
For the past 13 years, Darrell has specialized in intellectual property litigation,
including analysis of the infringement, validity and enforceability of patents.
SPHERIX
LEADING INNOVATION THROUGH INVENTION
22
23. OUR TRACK RECORD
Case Study 1: Portfolio Optimization
Through connections in the finance community, Mr. Hayes was retained to
evaluate a patent portfolio held by a company on the verge of bankruptcy.
The large IP portfolio of 70+ patents and patent applications provided world
wide patent coverage in the cosmetic laser space. Mr. Hayes created a
“special investment vehicle” to purchase and resell the IP portfolio. The
special investment vehicle raised funds from investors to purchase the patents,
as well as maintain and rehabilitate the portfolio. Mr. Hayes compiled a team
that included the inventor, industry experts, and the world’s largest patent
broker, to effectuate a sale of the entire portfolio in nine (9) months, for a
“pure return/gross return” of 600%.
SPHERIX
LEADING INNOVATION THROUGH INVENTION
23
24. OUR TRACK RECORD
Case Study 2: Patent Licensing
Mr. Hayes has also monetized IP through a litigation based licensing program.
As a result of relationships in the IP market place, Mr. Hayes identified
undervalued IP in the DSL communication space that was being spun off by
an operating company. An analysis of the portfolio showed that the most
value could be extracted by licensing the patents to infringing companies.
Over a two (2) year period, Mr. Hayes oversaw an aggressive licensing
program. The campaign involved litigation in multiple jurisdictions, against
some of the largest names in the telecommunications industry. At the
conclusion of the licensing program, Mr. Hayes effectuated a “pure return/
gross return” of 495%.
SPHERIX
LEADING INNOVATION THROUGH INVENTION
24
25. OUR TRACK RECORD
Case Study 3: Portfolio Optimization and Stock Price
Appreciation
Mr. Hayes was retained by a financially distressed publicly traded company to
monetize that company’s IP in the “cloud computing” space. Mr. Hayes restructured
the company’s management, drastically reduced capital expenditures and
prevented bankruptcy. Mr. Hayes further pulled together a team of experts in “cloud
computing” to restructure, package and market the company’s IP. Mr. Hayes’
connections resulted in both interest and offers from the largest names in the hightech field. After six (6) months, Mr. Hayes effectuated a sale of the company’s IP for a
seven figure profit.
Prior to Mr. Hayes’ involvement, the company’s stock was trading at $0.07 per share.
After Mr. Hayes’ involvement, the company declared a $0.34 per share dividend and
the stock traded as high as $0.51.
SPHERIX
LEADING INNOVATION THROUGH INVENTION
25
26. For More Information, Please Contact:
Spherix Inc.
Investor Relations Department
7927 Jones Branch Drive #3125
Tysons Corner, VA 22102
Tel.: (703) 992-9325
SPHERIX
LEADING INNOVATION THROUGH INVENTION
26